Evidence map›Paper›PMID 30761355›Full record

ArticleJournal of clinical and translational research2018

Post-hepatectomy liver regeneration in the context of bile acid homeostasis and the gut-liver signaling axis.

Lianne de Haan, Sarah J van der Lely, Anne-Loes K Warps, Quincy Hofsink, Pim B Olthof, Mark J de Keijzer, Daniël A Lionarons, Lionel Mendes-Dias, Bote G Bruinsma, Korkut Uygun and 6 more

Open access · diamondAbstract read
In one paragraph

Article in Journal of clinical and translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.International journal of biological sciences · 2021
    Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Lianne de HaanDepartment of Experimental Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Sarah J van der LelyDepartment of Experimental Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Anne-Loes K WarpsDepartment of Experimental Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Quincy HofsinkDepartment of Experimental Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Pim B OlthofDepartment of Experimental Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Mark J de KeijzerDepartment of Experimental Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Daniël A LionaronsOncogene Biology Laboratory, Francis Crick Institute, London, United Kingdom.
Lionel Mendes-DiasDepartment of Experimental Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Bote G BruinsmaDepartment of Experimental Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Korkut UygunCenter for Engineering in Medicine, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Hartmut JaeschkeDepartment of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, KS, United States.
Geoffrey C FarrellLiver Research Group, Australian National University Medical School at the Canberra Hospital, Canberra, Australian Capital Territory, Australia.
Narci TeohLiver Research Group, Australian National University Medical School at the Canberra Hospital, Canberra, Australian Capital Territory, Australia.
Rowan F van GolenDepartment of Experimental Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Tiangang LiDepartment of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, KS, United States.
Michal HegerDepartment of Experimental Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Amsterdam UMC Location University of Amsterdam · NLUtrecht University · NL

Funding

Nuclear Receptors in Liver Health and DiseaseP20GM103549 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI JAESCHKE, HARTMUT W. · 2012 to 2015
$8.1M
Pilot Grants ProgramP30GM118247 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI JAESCHKE, HARTMUT W. · 2016 to 2020
$5.5M
Autophagy and Drug-Induced Liver InjuryR01DK102142 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI DING, WEN-XING, JAESCHKE, HARTMUT W. · 2014 to 2022
$2.7M
Mitochondrial Dysfunction and Drug HepatotoxicityR01DK070195 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI JAESCHKE, HARTMUT W. · 2005 to 2010
$1.8M
The role of hepatic Sortlin 1 in diabetic dyslipidemiaR01DK102487 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI LI, TIANGANG · 2014 to 2018
$1.6M
NIDDK NIH HHS R01 DK070195NIDDK NIH HHS R01 DK102142NIDDK NIH HHS R01 DK102487NIGMS NIH HHS P20 GM103549NIGMS NIH HHS P30 GM118247
6 · The paper itself

Abstract

backgroundLiver regeneration following partial hepatectomy (PHx) is a complicated process involving multiple organs and several types of signaling networks. The bile acid-activated metabolic pathways occupy an auxiliary yet important chapter in the entire biochemical story. PHx is characterized by rapid but transient bile acid overload in the liver, which constitutes the first wave of proliferative signaling in the remnant hepatocytes. Bile acids trigger hepatocyte proliferation through activation of several nuclear receptors. Following biliary passage into the intestines, enterocytes reabsorb the bile acids, which results in the activation of farnesoid X receptor (FXR), the consequent excretion of fibroblast growth factor (FGF)19/FGF15, and its release into the enterohepatic circulation. FGF19/FGF15 subsequently binds to its cognate receptor, fibroblast growth factor receptor 4 (FGFR4) complexed with β-klotho, on the hepatocyte membrane, which initiates the second wave of proliferative signaling. Because some bile acids are toxic, the remnant hepatocytes must resolve the potentially detrimental state of bile acid excess. Therefore, the hepatocytes orchestrate a bile acid detoxification and elimination response as a protective mechanism in concurrence with the proliferative signaling. The response in part results in the excretion of (biotransformed) bile acids into the canalicular system, causing the bile acids to end up in the intestines. RELEVANCE FOR PATIENTS: Recently, FXR agonists have been shown to promote regeneration via the gut-liver axis. This type of pharmacological intervention may prove beneficial for patients with hepatobiliary tumors undergoing PHx. In light of these developments, the review provides an in-depth account of the pathways that underlie post-PHx liver regeneration in the context of bile acid homeostasis in the liver and the gut-liver signaling axis.

Indexed as

arnesoid X receptor enteraldetoxificationfibroblast growth factorhepatocyte proliferationmitotic signalingsurgerytransport and canalicular excretion

Identifiers

PMID30761355
PMCPMC6370335
OpenAlexW2789543207

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.